Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Giovanni Martinelli(University of Bologna), Valentina Robustelli(University of Bologna), Anna Ferrari(University of Bologna), Chiara Sartor(University of Bologna), Maria Chiara Abbenante(University of Bologna), Sarah Parisi(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Ilaria Iacobucci(St. Jude Children's Research Hospital), Viviana Guadagnuolo(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Enrica Imbrogno(University of Bologna), Enrico Derenzini(University of Milan)
Cited by 42
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627